| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Vemurafenib |
| Brand | Zelboraf® |
| Indication | For the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. |
| Assessment Process | |
| Rapid review commissioned | 23/12/2011 |
| Rapid review completed | 04/01/2012 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 04/05/2012 |
| NCPE assessment outcome | Reimbursement not recommended at the submitted price |
The NCPE believe that, at the submitted price, vemurafenib (Zelboraf®) is not cost effective for this indication
September 2014
The HSE has approved reimbursement following confidential price negotiations.